ProMIS Neurosciences, Inc.

NASDAQ:PMN

Biotechnology

Healthcare
$11.08 -0.14%

-$0.02 today

Market cap
$99.36M
Beta
-0.22
P/E (TTM)
-0.6
EPS (TTM)
-$4.62
52W Low $6.27High $27.40

Volume 0.13M

Average 0.07M

PMN Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

ProMIS Neurosciences, Inc.NASDAQ: PMN

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares growth accelerates

Q2 FY2026 weighted avg shares of 9.14M shares rose 555.8% year over year, ahead of the +249.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 40.1% from the prior quarter. Over 3 fiscal years it compounded at +80.2% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +555.8% holds above the trailing-twelve-month pace of +249.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
9.14M+40.1% QoQ
Last fiscal yearDec 2025
1.76M+69.4% YoY
LTMJun 2026
4.71M+249.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+555.8%——
1 year+69.4%——
3-year CAGR+80.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
1.76M USD
Year-over-year change
+69.4%

Weighted Avg Shares vs competitors

How PMN compares with its peers on the latest reported figures

  • PMN's LTM Jun 2026 weighted avg shares of 4.71M shares is the lowest of the 4 companies compared; the peer median is 7.76M shares.
  • Its year-over-year change of +249.7% is the highest of 3, against a peer median of +52.5%.
  • Over three fiscal years its annual growth of +80.2% compares with a peer median of +7.9%.
PMN Competitors Peer median
Weighted Avg Shares for PMN and competitors
Company Period LTM YoY 3-year CAGR
MPLTMapLight Therapeutics, Inc.LTM Mar 202643.04M +3.9%+2.0%
ANLAdlai Nortye Ltd.LTM Jun 20247.76M —+7.9%
EDSAEdesa Biotech, Inc.LTM Mar 20267.58M +101.1%+39.4%
PMNProMIS Neurosciences, Inc.LTM Jun 20264.71M +249.7%+80.2%
Peer median (excluding PMN) 7.76M+52.5%+7.9%

Competitors are the stored peer set for PMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue16.68K0000
Cost of Revenue5.85M010.44M00
Gross Profit(5.84M)0(10.44M)00
Gross Margin-35031.9%————
Research & Development4.95M16.09B7.88M10.64M33.38M
Selling, General & Admin3.31M7.29B6.38M6.19M6.79M
Operating Expenses4.63M23.38B8.45M16.83M40.17M
Depreciation & Amortization45.83K028.04K00
EBITDA(9.33M)(17.78B)(17.81M)2.86M(39.72M)
EBITDA Margin-55923.2%————
Operating Income(10.57M)(23.38B)(18.9M)(16.83M)(40.17M)
Operating Margin-63350.5%————
Interest Income4.73K0000
Interest Expense416.29K282.06M201.39K76.78K0
Other Income / Expenses(1.91M)5.32B1.39M19.61M448.16K
Income Before Tax(12.48M)(18.06B)(17.51M)2.78M(39.72M)
Pre-Tax Margin-74804.2%————
Income Tax Expense00000
Net Income(11.98M)(18.06B)(17.51M)2.78M(39.72M)
Net Margin-71819.3%————
EPS (Basic)(51.77)(60.25)(35.50)2.75(22.61)
EPS (Diluted)(51.77)(60.25)(35.50)2.75(22.61)
Weighted Avg Shares231.42K300.1K491.71K1.04M1.76M
Weighted Avg Shares (Diluted)231.43K300.1K491.71K1.06M1.76M

ProMIS Neurosciences, Inc.

NASDAQ:PMN

Intrinsic Alpha fair value

Locked

Current Price

$11.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.